Trials / Recruiting
RecruitingNCT06569498
Neoadjuvant Triple Therapy for Resectable HCC
Neoadjuvant Transcatheter Arterial Chemoembolization Combined With Lenvatinib Plus Cadonilimab for Resectable Hepatocellular Carcinoma: A Single-Arm Phase II Clinical Trial
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (estimated)
- Sponsor
- Fujian Provincial Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single-arm, multi-center, prospective phase II trial aimed at evaluating the efficacy and safety of neoadjuvant therapy with transarterial chemoembolization (TACE) combined with lenvatinib and camrelizumab (triple therapy) in patients with resectable hepatocellular carcinoma (HCC). The study plans to enroll 20 patients. The primary endpoints are major pathological response (MPR) rate and safety, while the secondary endpoints are recurrence-free survival (RFS), objective response rate (ORR), R0 resection rate, and overall survival (OS).
Conditions
Timeline
- Start date
- 2024-09-30
- Primary completion
- 2026-02-01
- Completion
- 2026-12-01
- First posted
- 2024-08-26
- Last updated
- 2024-10-15
Locations
6 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06569498. Inclusion in this directory is not an endorsement.